

Palliative/Supportive Care for the Patient with Cancer

SUMMARY

Cancer-associated malnutrition results in weight loss and a decline in lean body mass. Patients and families desire assistance in managing nutrition-related symptoms to maintain strength, energy and quality of life. Guidance is provided on handling side effects of treatment, dietary intake, and helping the patient to maintain control. Recent studies demonstrate early supportive care including nutrition can improve survival.

SCIENTIST BIOGRAPHY



Dr. Anne Coble Voss joined Abbott Nutrition in 1993 and is an Associate Research Fellow in the prestigious Volwiler Society of Abbott Laboratories.

Dr. Voss has international experience in the creation of guidelines for oncology and serves on the Oncology Evidence Analysis Library work group for the Academy of Nutrition and Dietetics. She has extensive experience in nutrition research in patients with cancer induced weight loss and has developed novel product for adults with cancer induced weight loss.

Prior to joining Abbott Nutrition, Dr. Voss worked for the College of Medicine, The Ohio State University, The Ohio State University Medical Center, and Johns Hopkins Hospital. She has published over 75 journal articles, monographs, and book chapters, and is listed in *Who's Who in the World* for her discovery of the *de novo* biosynthetic pathway of the omega-3 fatty acid, DHA (docosahexaenoic acid), important in the development of brain and retina in newborn babies.

Dr. Voss earned her undergraduate degree in Medical Dietetics and a PhD in nutritional biochemistry from The Ohio State University. She recently received the Distinguished Alumni Award from The Ohio State University, a President's Award, and a Luminary Award from Abbott Laboratories.



Mary Ann Cockram joined Abbott Nutrition in 2003 and is a Research Scientist in Scientific and Medical Affairs. She provides clinical support and nutrition science education to both internal and external customers for the adult therapeutic critical care, renal, and oncology products.

Mary Ann earned a Bachelor of Science degree in Home Economics from Valparaiso University in Valparaiso, Indiana, and a Master of Science degree in Clinical Nutrition from Rush University in Chicago, Illinois. Her previous clinical experience includes working with adult patients in the hospital, nursing home, and clinical research settings. Mary Ann is a member of the Academy of Nutrition and Dietetics and the American Society for Parenteral and Enteral Nutrition.





INTRODUCTION

Palliative or supportive care may be offered to a patient when all means of curative intent have been exhausted. A program dedicated to symptom control that includes nutrition intervention may help improve quality of life and functioning in advanced cancer patients¹. Benefits in a variety of cancer types have been shown^{2,3}. Patients and families struggling with advanced cancer, as well as their physicians, highly value the control of symptoms, maintenance of nutrition, function and improvement in quality of life⁴⁻⁶.

Nutrition is an important component in the care and management of patients with advanced cancer⁷.

- The focus of nutrition care is to manage nutrition-related symptoms and adverse effects.
- The aim of nutrition care is to maintain the patient's strength and energy so as to enhance quality of life, foster independence, and promote the ability to perform activities of daily living (ADLs).

Nutrition should be provided as tolerated with emotional support, respect, and an awareness of the individual patient's needs and wishes. The pleasurable aspects of eating should be emphasized, with less concern for the quantity or nutrient content of foods consumed⁸.

COUNSELING SUGGESTIONS

Suggestions for providing counseling to the patient and family include the following⁹⁻¹⁴

- Provide intervention when symptoms and adverse effects, such as pain, constipation, diarrhea, nausea, or discomfort associated with eating, diminish the patient's quality of life
- Encourage patients to take pain and supportive care medications as prescribed or contact their health care provider to modify regimens. Pain can greatly interfere with a patient's appetite.
- Prepare and offer small portions of foods. Patients may not have an interest in eating leftovers.
- Encourage the patient to eat small, more frequent meals, which may be better tolerated than three large meals a day.
- Provide favorite foods while monitoring the patient's current likes and dislikes. Tastes and preferences frequently change.
- Recommend foods that require minimal handling and effort to eat.
- Offer all varieties of beverages and liquids to help with hydration.
- Oral nutrition supplements are nutritionally concentrated, easy to swallow, and may help with hydration.
- When possible, encourage the patient to make eating a more pleasant experience by sharing meals with others, at a table, and without the presence of interfering medical equipment.
- Help patients focus on the idea of "eating for strength" instead of eating based on appetite.
- Allow the patient to control how much and how often he or she eats. If the patient does not feel like eating, do not force food; simply remove it without comment.
- Encourage activity as tolerated to stimulate appetite.
- Support the patient's decision to request or decline nutrition support.





• Reassure patients that you understand about choices they are making in regards to food and their health. Symptom management and the patient's comfort are key to supporting the patient's wishes.

BEST SUPPORTIVE CARE

Best supportive care is becoming an important aspect of anti-cancer treatment to achieve optimal results. Patients who experience cancer induced weight loss may experience malnutrition. Malnutrition is defined as "a state of nutrition in which a deficiency (or imbalance) of energy, protein and other nutrients cause measureable adverse effect on tissue/body form (body shape, size and composition) and function and clinical outcome"¹⁵. The consequences of malnutrition can include impaired immune response¹⁶, reduced muscle strength^{17,18}, increased fatigue¹⁹, impaired wound healing¹⁶, impaired psycho-social function¹⁹, reduced quality of life²⁰⁻²², reduced response and tolerance to prescribed oncology treatment²³, and potentially increased costs of health care and hospital length of stay²⁴. Early identification of cancerassociate malnutrition and intervention is imperative for improved outcomes²⁵.

Palliative care is more than symptom control. Much of the current literature in advanced cancer concludes that **early** palliative/supportive care can improve quality of life and survival²⁶. These outcomes were better in patients receiving a systematic, multi-disciplinary approach to palliative care that included nutrition support. The problem comes in defining when a patient is terminal. It is challenging to determine when there is no longer a benefit to nutrition support as part of palliative care. Therapeutic nutrition interventions may provide improved quality of life²¹ and survival²² but should always be guided by the patient's wishes to provide symptom control vs. more aggressive nutrition intervention.

CANCER CACHEXIA

Patients may have a cachexia syndrome in addition to malnutrition. Cachexia does not mean end of life or hospice. There are three stages of cancer cachexia: Pre-cachexia, cachexia and refractory cachexia²⁷. Nutrition assessment and intervention is most effective if provided in the states of pre-cachexia and cachexia. The metabolic response to cancer is heterogeneous, so it is important to intervene and manipulate the factors that are behavior-related, to address the direct causes of decreased intake (obstruction, dysphagia) and address the secondary causes (pain, depression, fatigue, gastrointestinal function) because "symptom management alone can improve survival in patients with advanced cancer".²⁸ The stages of cancer cachexia are described below (Table 1).

In pre-cachexia, early clinical and metabolic signs such as loss of appetite and impaired glucose tolerance are present. These signs can precede substantial involuntary weight loss (i.e., up to 5%). The risk of progression is variable and depends on cancer type, stage, presence of systemic inflammation, low food intake and lack of response to anti-cancer therapy²⁷. The focus must change from end-stage wasting to supporting patients' nutritional and functional state throughout the increasingly complex and prolonged course of anti-cancer treatment. When inadequate intake predominates (malnutrition), this can be managed by conventional nutritional support. In the presence of systemic inflammation or altered metabolic state (cachexia), a multi-modal approach including novel therapeutic agents may be required.





"For all patients, oncologists should consider three supportive care issues: ensuring sufficient energy and protein intake, maintaining physical activity to maintain muscle mass and (if present) reducing systemic inflammation."²⁹

Table 1. Stages of Cancer Cachexia

Pre-cachexia: Characterized by early clinical and metabolic signs such as loss of appetite and impaired glucose tolerance; can precede substantial involuntary weight loss (i.e., up to 5%). The risk of progression is variable and depends on cancer type, stage, presence of systemic inflammation, low food intake and lack of response to anti-cancer therapy.

Cancer cachexia: A multi-factorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. The pathophysiology is characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism.

Refractory cachexia: May be a result of very advanced cancer (pre-terminal) or the presence of rapidly progressive cancer unresponsive to anti-cancer therapy. This stage is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible or appropriate. Refractory cachexia is characterized by a low performance score (e.g., WHO grade 3 or 4) and a life expectancy of less than three months.

CONCLUSION

Consensus recommendations and guidelines recommend the early identification of patients with cancerassociated malnutrition that includes effective nutrition intervention and symptom control. Maintenance of muscle mass is key to preserving strength, quality of life, treatment tolerance and survival.





References:

- **1.** Gagnon B, Murphy J, Eades M, et al. A prospective evaluation of an interdisciplinary nutritionrehabilitation program for patients with advanced cancer. *Curr Oncol.* Dec 2013;20(6):310-318.
- 2. Eades M, Murphy J, Carney S, et al. Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: review of clinical experience. *Head Neck*. 2013;35(3):343-349.
- **3.** Chasen MR, Bhargava R. A rehabilitation program for patients with gastroesophageal cancer--a pilot study. *Support Care Cancer.* May 2010;18 Suppl 2:S35-40.
- 4. ASCO-ESMO. ASCO-ESMO consensus statement on quality cancer care. *J Clin Oncol.* Jul 20 2006;24(21):3498-3499.
- Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. *J Clin Oncol.* Mar 10 2012;30(8):880-887.
- 6. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. *J Clin Oncol.* Feb 20 2011;29(6):755-760.
- Trentham K. Nutrition management of oncology patients in palliative and hospice settings. In: Elliot LL, N. Bergerson, S. Trujillo, E., ed. *Oncology Nutrition for Clinical Practice*. Chicago, IL: Oncology Nutrition Dietetic Practice Group, The Academy of Nutrition and Dietetics; 2013:241-247.
- 8. Elliott LL, R. McIver, J. Palliative care and advanced cancer. *The Complete Resource Kit for Oncology Nutrition* <u>http://publications.webauthor.com/pubs/oncology/Palliative-Care</u>. Accessed August 18, 2014.
- **9.** Maillet JO, Potter RL, Heller L. Position of the American Dietetic Association: ethical and legal issues in nutrition, hydration, and feeding. *J Am Diet Assoc.* May 2002;102(5):716-726.
- **10.** Donnelly S, Walsh D, Rybicki L. The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. *J Palliat Care*. Spring 1995;11(1):27-32.
- **11.** Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. *CA Cancer J Clin.* Nov-Dec 2006;56(6):323-353.
- **12.** McCallum PD, Fornari A. Nutrition in palliative care. In: Elliot L, Molseed L, McCallum PD, Grant B, eds. *The Clinical Guide to Oncology Nutrition*. 2nd ed. Chicago, IL: American Dietetic Association; 2006:201-207.
- **13.** Stevens E. Promoting self-worth in the terminally ill. *Eur J Palliat Care.* 1996;3:60-64.
- **14.** WHO definition of palliative care. 2010; <u>www.who.int/cancer/palliative/en</u>. Accessed October 25, 2012.
- **15.** Elia M. Screening for malnutrition: a multidisciplinary responsibility. Development and use of the 'Malnutrition Universal Screening Tool' ('MUST') for adults. *British Association of Parenteral and Enteral Nutrition*: MAG, a Standing Committee of BAPEN 2012.
- **16.** Demling RH. Nutrition, anabolism, and the wound healing process: an overview. *Eplasty.* 2009;9:e9.
- **17.** von Meyenfeldt M FM, Voss A, Fearon K, Moses A, van Geenen R, Gouma DJ, Roy A, Giacosa A, van Gossum A, Tisdale M. Weight gain is associated with improved quality of life in patients with cancer cachexia consuming an energy and protein dense, high n-3 fatty acid oral supplement. *Proc Am Soc Clin Oncol.* 2002;21:385.
- **18.** Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy





and protein dense oral supplement enriched with n-3 fatty acids. *British Journal of Cancer.* 2004;90(5):996-1002.

- **19.** Silver HJ, de Campos Graf Guimaraes C, Pedruzzi P, et al. Predictors of functional decline in locally advanced head and neck cancer patients from south Brazil. *Head & Neck.* Sep 2010 2010;32(9):1217-1225.
- **20.** Marín Caro MM, Laviano A, Pichard C. Nutritional intervention and quality of life in adult oncology patients. *Clinical Nutrition*. 2007;26(3):289-301.
- **21.** Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Cancer: Disease and nutrition are key determinants of patients' quality of life. *Supportive Care in Cancer.* Apr 2004 2004;12(4):246-252.
- **22.** Davidson W, Ash S, Capra S, Bauer J. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. *Clinical Nutrition.* 2004;23(2):239-247.
- **23.** Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for improving treatment tolerance in cancer patients. *Current Opinion in Oncology*. 2011;23(4):322-330.
- 24. Odelli C, Burgess D, Bateman L, et al. Nutrition Support Improves Patient Outcomes, Treatment Tolerance and Admission Characteristics in Oesophageal Cancer. *Clinical Oncology*. 2005;17(8):639-645.
- **25.** Bozzetti F, Mariani L, Lo Vullo S, et al. The nutritional risk in oncology: a study of 1,453 cancer outpatients. *Support Care Cancer.* Aug 2012;20(8):1919-1928.
- **26.** Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic nonsmall-cell lung cancer. *New England Journal of Medicine.* 2010 Aug 19 2010;363(8):733-742.
- **27.** Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol.* May 2011;12(5):489-495.
- **28.** Fearon KC. Cancer cachexia and fat-muscle physiology. *N Engl J Med.* Aug 11 2011;365(6):565-567.
- **29.** Aapro M, Arends J, Bozzetti F, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. *Annals of Oncology*. 2014;25(8):1492-1499.

